ClinicalTrials.gg
RecruitingNCT04432025BY-PLUSUpdated Aug 8, 2022

Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus

An interventional study of Bariatric surgery + goal directed medical therapy and Bariatric surgery in Obesity and Type 2 Diabetes, sponsored by Imperial College London. Recruiting at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Obesity by Imperial College London — 5 open to participants now, 6 under way, none of them phase 3. Obesity · Imperial College London.

Planned enrollment
3rd of 27
150 · median 53
Started
2021
the only one that year
No phase
21 of 36
4 open now
Registered
32nd of 36
by date

Among the 36 studies in Obesity by Imperial College London, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 21 with no phase, and was the 32nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 36 studies in Obesity by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Obesity by Imperial College London, or all of them as a file.
02

Study summary

The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

03

Conditions studied

  • Obesity
  • Type 2 Diabetes

Keywords

  • obesity
  • type 2 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • eligible for bariatric surgery according to NICE guidelines (GC 189)
  • Type 2 diabetes mellitus
  • >30kg/m2

Exclusion criteria

Exclusion Criteria:

  • Recent hospitalisation in the past 30 days
  • Recurrent hypoglycaemic episodes
  • Recurrent hypotensive episodes
  • to bariatric surgery
  • Previous bariatric surgery
  • Current pregnancy
  • Breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Control

    Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner

    Procedure: Bariatric surgery

  • Experimental
    Intervention

    Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.

    Procedure: Bariatric surgery + goal directed medical therapy

Interventions

  • ProcedureBariatric surgery + goal directed medical therapy

    Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids

  • ProcedureBariatric surgery

    Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner

06

What researchers measure

Primary outcomes

  1. Proportion of patients in each group reaching the composite end point

    BP\<130/80, HbA1c\<6.5%, LDL\<2.6mmol/L

    Time frame: 5 years

  2. Proportion of patients reaching end point for glycemic control

    HbA1c\<6.5%

    Time frame: 1 year

Secondary outcomes

  1. Change in body weight

    Change in body weight from baseline (kg)

    Time frame: 5 years

  2. Change in BMI

    Change in BMI from baseline (kg/m2)

    Time frame: 5 years

  3. Change in waist circumference

    Change in waist circumference (cm)

    Time frame: 5 years

  4. Change in lipid control

    Proportion of patients achieving good lipid control (LDL\<2.6mmol/L)

    Time frame: 5 years

  5. Change in glycaemic control

    Change in long term glycaemic control(HbA1c)

    Time frame: 5 years

  6. Change in blood pressure

    Proportion of patients achieving BP\<130/80mmHg

    Time frame: 5 years

  7. Change in liver function

    Proportion of patients achieving normal liver function tests (ALT, GGT, ALP, AST)

    Time frame: 5 years

  8. Change in renal function

    Proportion of patients with normal renal function (plasma Cr, eGFR)

    Time frame: 5 years

  9. Change in inflammatory markers

    Reduction in CRP

    Time frame: 5 years

  10. Change in urine albumin: creatinine ratio

    Proportion of patients in each group with a uACR\<30

    Time frame: 5 years

  11. Change in quality of life

    Quality of life change as determined by SF-36 and MPH-H

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sudlow A, Miras AD, Cohen RV, Kahal H, Townley J, Heneghan H, Le Roux C, Pournaras DJ. Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study. BMJ Open. 2022 Jul 25;12(7):e054313. doi: 10.1136/bmjopen-2021-054313. PubMed 35879015 ↗

Individual participant data

Plan to share: Yes — The authors shall make data available to the scientific community with as few restrictions as feasible, ensuring anonymisation, while retaining exclusive use until the publication of major outputs.

Supporting information: Study protocol

Time frame: 6 months

Access criteria: Free access

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Apr 2027, 72 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 72 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 16, 2020
StartActual
Apr 1, 2021
Primary completionEst.
Apr 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04432025
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Apr 1, 2021
Primary completion
Apr 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 8, 2022

Study contacts

Alexander Miras, MRCP
Contact
a.miras@nhs.net
: +44 (0)20 8383 3242

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion